EDITAS MEDICINE INC.

Editas Medicine Announces First Quarter 2022 Results and Business Updates

04 май 2022 06:45:00 Источник Nasdaq GlobeNewswire

Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting

02 май 2022 16:31:07 Источник Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

27 апр 2022 06:55:00 Источник Nasdaq GlobeNewswire

Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia

26 апр 2022 09:00:03 Источник Nasdaq GlobeNewswire

Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer

14 апр 2022 07:30:00 Источник Nasdaq GlobeNewswire

Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

11 апр 2022 09:00:00 Источник Nasdaq GlobeNewswire

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

08 апр 2022 13:00:00 Источник Nasdaq GlobeNewswire

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

28 фев 2022 16:01:00 Источник Nasdaq GlobeNewswire

Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

24 фев 2022 06:30:00 Источник Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update

16 фев 2022 06:15:00 Источник Nasdaq GlobeNewswire

Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference

10 янв 2022 07:00:02 Источник Nasdaq GlobeNewswire

Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 янв 2022 06:58:00 Источник Nasdaq GlobeNewswire

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

20 дек 2021 07:00:00 Источник Nasdaq GlobeNewswire

Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting

12 дек 2021 18:00:00 Источник Nasdaq GlobeNewswire

Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting

12 ноя 2021 07:00:02 Источник Nasdaq GlobeNewswire

Editas Medicine Announces Third Quarter 2021 Results and Business Updates

08 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition

04 ноя 2021 09:02:00 Источник Nasdaq GlobeNewswire

Editas Medicine Names Bernadette Connaughton to Board of Directors

28 окт 2021 09:00:02 Источник Nasdaq GlobeNewswire

Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update

25 окт 2021 16:01:00 Источник Nasdaq GlobeNewswire

Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress

20 окт 2021 09:00:01 Источник Nasdaq GlobeNewswire